Zimmer Biomet(US:ZBH) Prnewswire·2026-02-18 14:05Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) due to concerns over the company's "high confidence" assurances regarding its 2025 revenue targets following a 15% stock decline and reduced revenue guidance [1] Group 1: Investigation Focus - The investigation examines whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly in emerging markets [1] - The firm is looking into potential violations of federal securities laws related to overly optimistic guidance while concealing operational disruptions [1] Group 2: Recent Developments - On November 5, 2025, Zimmer Biomet reported a year-over-year organic revenue growth of only 5%, significantly missing its forecast and reducing its top-line organic revenue growth forecast to 4% [1] - The company disclosed distributor order cancellations in emerging markets, particularly in the Middle East and Eastern Europe, and acknowledged serious headwinds in Latin America [1] - Following these revelations, CEO Ivan Tornos stated the need for more measured external commentary, which contributed to the 15% drop in stock price on the same day [1] Group 3: Previous Assurances - In an August 7, 2025 earnings call, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, attributing it to emerging markets distributor purchases [1] - These optimistic statements led to a 7% increase in the company's share price on that day [1]